SCHEMBL4192895

SCHEMBL4192895

CC(C)(C)OC(=O)N1CC(C(=O)c2ccc(Br)cc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.48
USP30 Q70CQ3 2/20 0.46
FPR2 P25090 2/20 0.46
FPR3 P25089 1/20 0.45
ESRRB O95718 1/20 0.44
ESR1 P03372 1/20 0.44
ESRRA P11474 1/20 0.44
ESRRG P62508 1/20 0.44
KMT2A Q03164 3/20 0.44
POLB P06746 1/20 0.44
ABL1 P00519 1/20 0.44
RIN1 Q13671 1/20 0.44
MGLL Q99685 1/20 0.43
HSD11B1 P28845 1/20 0.43
GPR119 Q8TDV5 2/20 0.42
KCNK3 O14649 1/20 0.42
KCNK9 Q9NPC2 1/20 0.42
MEN1 O00255 1/20 0.42
NR1H2 P55055 1/20 0.41
PTPN2 P17706 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1991541 0.89 KMT2A (0.52) USP30FPR2FPR3KMT2APOLB
SCHEMBL29537844 0.89 KMT2A (0.52) USP30FPR2FPR3KMT2APOLB
SCHEMBL1991537 0.89 KMT2A (0.52) USP30FPR2FPR3KMT2APOLB
SCHEMBL4235957 0.86 MGLL (0.56) FPR2KMT2APOLBABL1RIN1
SCHEMBL20568872 0.86 ABL1 (0.44) RORCUSP30KMT2AABL1RIN1
SCHEMBL21381625 0.86 HSD11B1 (0.48) USP30KMT2AABL1RIN1HSD11B1
SCHEMBL3019433 0.86 MEN1 (0.58) KMT2AABL1RIN1MGLLMEN1
SCHEMBL2882463 0.85 KDM4E (0.51) RORCUSP30KMT2AGPR119MEN1
SCHEMBL9947987 0.84 STS (0.54) KMT2APOLBMGLLHSD11B1GPR119
SCHEMBL19726024 0.83 ABL1 (0.42) USP30KMT2AABL1RIN1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612360-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2026-04-28 US disclosed
US-12595230-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2026-04-07 US disclosed
US-20260035363-A1 COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS MERCK SHARP & DOHME LLC (US) 2026-02-05 US disclosed
US-12459933-B2 Compounds and methods of use thereof as antibacterial agents MERCK SHARP & DOHME LLC (US) 2025-11-04 US disclosed
US-20250263390-A1 NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2025-08-21 US disclosed
US-20250255848-A1 SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2025-08-14 US disclosed
EP-4508030-A1 SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-02-19 EP disclosed
EP-4508029-A1 SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-02-19 EP disclosed
CN-119013252-A Substituted 6, 7-dihydro-5H-benzo [7] rotaene derivatives, process for their preparation and their therapeutic use 赛诺菲 2024-11-22 CN disclosed
CN-119013251-A Substituted 6, 7-dihydro-5H-benzo [7] rotaene derivatives, process for their preparation and their therapeutic use 赛诺菲 2024-11-22 CN disclosed
CN-107001259-B Substituted azetidine derivatives as TAAR ligands 豪夫迈·罗氏有限公司 2019-12-06 CN disclosed
US-10023559-B2 Substituted azetidine derivatives HOFFMAN-LA ROCHE INC. (US) 2018-07-17 US disclosed
EP-3186224-A1 SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS F. Hoffmann-La Roche AG (CH) 2017-07-05 EP disclosed
US-20170144994-A1 SUBSTITUTED AZETIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-05-25 US disclosed
WO-2016030310-A1 SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS F. HOFFMANN-LA ROCHE AG (CH) 2016-03-03 WO disclosed
US-20120302547-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2012-11-29 US disclosed
US-8263772-B2 MCH receptor antagonists ELI LILLY AND COMPANY (US) 2012-09-11 US disclosed
US-20090093456-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-04-09 US disclosed
EP-2029609-A2 NOVEL MCH RECEPTOR ANTAGONISTS Eli Lilly & Company (US) 2009-03-04 EP disclosed
WO-2007146758-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612360-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof ESRRA, FSHR, GPER1 RORC 360/4885USP30 2958/4885FPR2 487/4885
US-20250263390-A1 NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF GPER1, ESR2, ESRRA RORC 519/4885USP30 1561/4885FPR2 909/4885
US-10023559-B2 Substituted azetidine derivatives HTR1B, MTNR1B, DRD2 RORC 1631/4885USP30 1754/4885FPR2 1432/4885
US-12459933-B2 Compounds and methods of use thereof as antibacterial agents NDUFB7, MRPL21, SQLE RORC 166/4885USP30 4734/4885FPR2 1261/4885
US-20250255848-A1 SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF CYP19A1, FSHR, GPER1 RORC 515/4885USP30 3145/4885FPR2 567/4885
US-20170144994-A1 SUBSTITUTED AZETIDINE DERIVATIVES HTR1B, MTNR1B, DRD2 RORC 1631/4885USP30 1754/4885FPR2 1432/4885
US-12595230-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof FSHR, CYP19A1, GPER1 RORC 320/4885USP30 2012/4885FPR2 1794/4885
US-20120302547-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R RORC 128/4885USP30 2640/4885FPR2 850/4885
US-20260035363-A1 COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS CBR3, CBR1, NR3C2 RORC 34/4885USP30 4742/4885FPR2 335/4885
US-20090093456-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R RORC 128/4885USP30 2406/4885FPR2 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.